Loading…
Syncom Formulations (India) (SYNCOMF)₹20.10−4.33%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Syncom Formulations (India) reported sales of ₹126 Cr, up 7.7% from Jun 2025, and net profit of ₹25.06 Cr, up 56.3% year on year. For the year to Mar 2026, sales were ₹488 Cr and net profit ₹76.14 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 63.92 | 64.98 | 74.99 | 86.89 | 102 | 128 | 149 | 117 | 122 | 115 | 135 | 126 |
| Expenses | 56.93 | 57.93 | 64.95 | 76.88 | 89.95 | 113 | 131 | 101 | 103 | 93.89 | 113 | 98.96 |
| Operating Profit | 6.02 | 7.02 | 9.03 | 10.03 | 12.03 | 15.04 | 18.06 | 16.04 | 18.05 | 21.07 | 22.06 | 26.08 |
| OPM % | 10.0% | 11.0% | 13.0% | 12.0% | 12.0% | 12.0% | 12.0% | 14.0% | 15.0% | 18.0% | 16.0% | 21.0% |
| Other Income | 4.01 | 5.01 | 3.01 | 1.01 | 4.01 | 4.01 | 7.02 | 6.01 | 5.01 | 6.01 | 15.02 | 8.02 |
| Interest | 1.01 | 1.01 | 1.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 | 1.99 | 1.99 |
| Profit before tax | 8.01 | 8.99 | 10.01 | 9.99 | 14.99 | 17.01 | 23.01 | 19.99 | 21.99 | 25.01 | 34.01 | 31.98 |
| Tax % | 23.0% | 25.0% | 26.0% | 24.0% | 25.0% | 25.0% | 24.0% | 22.0% | 25.0% | 25.0% | 25.0% | 23.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | 7.01 | 7.01 | 7.01 | 8.01 | 11.03 | 13.03 | 18.03 | 16.03 | 17.02 | 19.03 | 25.04 | 25.06 |
| EPS (Rs) | 0.08 | 0.08 | 0.09 | 0.09 | 0.13 | 0.15 | 0.18 | 0.18 | 0.19 | 0.21 | 0.28 | 0.25 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 173 | 184 | 185 | 216 | 222 | 262 | 463 | 488 | 498 |
| Expenses | 155 | 167 | 168 | 196 | 202 | 232 | 407 | 412 | 409 |
| Operating Profit | 18.03 | 17.05 | 17.05 | 20.04 | 20.06 | 30.09 | 54.17 | 77.22 | 87.26 |
| OPM % | 11.0% | 9.0% | 9.0% | 9.0% | 9.0% | 11.0% | 12.0% | 16.0% | 17.5% |
| Other Income | 1.01 | 3.01 | 3.01 | 12.03 | 15.03 | 14.03 | 17.05 | 31.04 | 34.06 |
| Interest | 0.00 | 0.00 | 0.00 | 2.01 | 3.01 | 5.01 | 1.01 | 1.01 | 0.00 |
| Depreciation | 2.99 | 2.99 | 2.99 | 3.99 | 4.99 | 4.99 | 4.99 | 6.98 | 5.96 |
| Profit before tax | 16.01 | 15.99 | 16.01 | 25.98 | 26.99 | 34.01 | 66.04 | 101 | 113 |
| Tax % | 38.0% | 36.0% | 34.0% | 24.0% | 24.0% | 25.0% | 25.0% | 24.0% | — |
| Exceptional items | −1.01 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 0.00 | 0.00 | 0.00 |
| Net Profit | 10.02 | 10.02 | 11.03 | 20.04 | 20.04 | 25.03 | 49.09 | 76.14 | 86.15 |
| EPS (Rs) | 0.12 | 0.14 | 0.14 | 0.24 | 0.22 | 0.28 | 0.52 | 0.82 | 0.93 |
| Dividend payout % | 16.0% | 15.0% | 15.0% | 13.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 78.13 | 78.18 | 78.24 | 86.28 | 94.32 | 94.32 | 94.35 | 94.25 |
| Reserves | 21.98 | 30.95 | 38.97 | 136 | 162 | 194 | 248 | 321 |
| Borrowings | 6.01 | 6.01 | 12.02 | 58.15 | 83.14 | 72.18 | 5.02 | 1.01 |
| Other Liabilities | 31.13 | 61.08 | 50.08 | 28.14 | 39.19 | 44.21 | 67.32 | 118 |
| Total Liabilities | 138 | 175 | 180 | 309 | 379 | 406 | 414 | 535 |
| Fixed Assets | 46.03 | 46.01 | 55.04 | 93.99 | 91.07 | 120 | 125 | 184 |
| CWIP | 0.00 | 4.99 | 0.00 | 5.99 | 25.97 | 0.00 | 0.00 | 0.00 |
| Investments | 6.02 | 23.07 | 36.10 | 43.12 | 64.20 | 66.28 | 93.28 | 109 |
| Other Assets | 85.20 | 101 | 89.17 | 165 | 197 | 219 | 196 | 242 |
| Inventories | 11.04 | 15.06 | 10.03 | 20.06 | 21.07 | 21.07 | 41.17 | 63.25 |
| Trade receivables | 31.10 | 46.17 | 46.16 | 68.19 | 76.32 | 103 | 108 | 110 |
| Cash & equivalents | 7.01 | 6.01 | 7.01 | 0.00 | 9.01 | 68.06 | 1.01 | 6.01 |
| Total Assets | 138 | 175 | 180 | 309 | 379 | 406 | 414 | 535 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 0.00 | 23.90 | 13.96 | 15.96 | 10.96 | −5.98 | 22.92 | 57.81 |
| Cash from investing activity | 1.01 | −23.03 | −18.02 | −27.04 | −45.06 | 83.09 | −18.03 | −51.04 |
| Cash from financing activity | 0.99 | −1.99 | 4.98 | 7.96 | 34.84 | −14.93 | −67.69 | −2.99 |
| Net cash flow | 1.99 | −0.99 | 0.99 | −1.99 | 0.99 | 61.82 | −62.83 | 3.99 |
| Capex | 2.99 | 2.99 | 12.98 | 10.98 | 20.97 | 7.99 | 9.99 | 11.99 |
| Free cash flow | −3.01 | 21.03 | 2.01 | 5.01 | −10.02 | −14.03 | 13.02 | 46.11 |
| CFO / OP % | 32.1% | 176.1% | 108.0% | 113.1% | 86.1% | 7.1% | 70.1% | 105.1% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor days | 66 | 91 | 91 | 114 | 124 | 144 | 85 | 82 |
| Inventory days | 34 | 43 | 29 | 51 | 55 | 49 | 49 | 81 |
| Days payable | 63 | 130 | 92 | 36 | 53 | 56 | 51 | 96 |
| Cash conversion cycle | 37 | 4 | 27 | 129 | 126 | 137 | 83 | 68 |
| Working capital days | 84 | 39 | 41 | 32 | −5 | 50 | 94 | 163 |
| ROCE % | 16.1% | 15.1% | 13.1% | — | 10.1% | 11.1% | 19.1% | 27.1% |
For the Jun 2026 quarter, Syncom Formulations (India) reported sales of ₹126 Cr, up 7.7% year on year and net profit of ₹25.06 Cr, up 56.3% year on year. The operating margin was 21.0%.
Syncom Formulations (India)'s sales for the year to Mar 2026 were ₹488 Cr; over the last twelve months they were ₹498 Cr.
Net profit for the year to Mar 2026 was ₹76.14 Cr, and ₹86.15 Cr over the last twelve months. Earnings per share over the same trailing period were ₹0.93.
Syncom Formulations (India) reported borrowings of ₹1.01 Cr at Mar 2026, against cash and equivalents of ₹6.01 Cr.
Cash from operations was ₹57.81 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹46.11 Cr.